Table 3:
Patient characteristics of the GHS cohort.
| (n = 51) | |
|---|---|
| Clinical characteristics | |
| Sex, n (%) | |
| Male | 27 (52.9) |
| Female | 24 (47.1) |
| Age | |
| Median, n (range) | 67 (20–90) |
| Location of tumor, n (%) | |
| Trunk | 31 (60.8) |
| Extremity | 20 (39.2) |
| T-stage, n (%) | |
| T1a or T1b | 1 (2.0) |
| T2a | 0 (0) |
| T2b or T3a | 19 (37.3) |
| T3b or T4a | 20 (39.2) |
| T4b | 11 (21.6) |
| Unknown | 0 (0) |
| Stage, n (%) | |
| I | 0 (0) |
| II | 25 (49.0) |
| III | 26 (51.0) |
| Pathologic characteristics | |
| Depth (mm) | |
| Median, n (range) | 3.45 (0.65–13) |
| Ulceration, n (%) | |
| Absent | 23 (45.1) |
| Present | 28 (54.9) |
| Unknown | 0 (0) |
| Microsatellite lesions, n (%) | |
| Absent | 43 (84.3) |
| Present | 7 (13.7) |
| Unknown | 1 (2.0) |
| TILs | |
| Absent | 13 (25.5) |
| Non-brisk | 32 (62.7) |
| Brisk | 5 (9.8) |
| Unknown | 1 (2.0) |
| SLNB status, n (%) | |
| Completed | 47 (92.2) |
| Positive, n (% of completed) | 19 (40.4) |
| Negative, n (% of completed) | 28 (59.6) |
| Not completed | 4 (7.8) |
| Outcome characteristics | |
| Patient follow-up (months) | |
| Median, n (range) | 56 (9–142) |
| DMR, n (%) | |
| Distant recurrence | 29 (56.9) |
| No recurrence or local recurrence only | 22 (43.1) |
| OS, n (%) | |
| Alive (at least 2 years) | 21 (41.2) |
| Dead | 30 (58.8) |
| DSS, n (%) | |
| Alive or NED at death | 25 (49.0) |
| Median follow-up (months) | 93 |
| Dead with melanoma | 19 (37.3) |
| Median follow-up (months) | 28 |
| Unknown | 7 (13.7) |
Abbreviations: DMR, distant metastatic recurrence; DSS, disease-specific survival; NED, no evidence of disease; OS, overall survival